Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense, Inc. Announces Patent Issued For New MRI Reporter Gene

April 20, 2011 - Pittsburgh, Pennsylvania

Celsense, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application 11/080,732 with claims covering its MRI reporter gene product, Gene Sense.

Gene Sense is a DNA-based reporter that 'programs' cells to express their own contrast agent. Gene Sense is used for visualizing the delivery of cellular and gene therapeutics, imaging transgenic animal models, and pharmacological profiling of drug candidates. This enabling technology is used for pre-clinical imaging studies of gene expression in vivo, as well as for long-term MRI cell labeling and tracking.

Distributed by plasmid, Gene Sense can label cells in vitro or in vivo using off-the-shelf vectors. The Gene Sense product is a metalloprotein-based MRI contrast agent that incorporates endogenous iron from the body to gain potency. Detection of Gene Sense relies on conventional 1H MRI and does not require a substrate or special diet. 

The new patent includes a broad set of claims covering nucleic acid sequences that bind endogenous metals in mammalian cells, causing them to express contrast in MRI. The Gene Sense technology was invented by Drs. Eric Ahrens and Clinton Robison at Carnegie Mellon University. The technology was licensed exclusively to Celsense from Carnegie Mellon University in 2005. 

“Celsense is in a strong leadership position in the offering of cellular and molecular imaging tools for the life science industry, and we are pleased to be able to add this patent to our intellectual property portfolio,” said Charlie O’Hanlon, President and CEO of Celsense.

About Celsense, Inc.
Celsense, Inc. offers products that enable the non-invasive imaging of cells in vivo using MRI.  The mission of the company is to be the standard for cellular imaging in human health.

Celsense, Inc. has three reagent families for MRI of cells currently on the market for pre-clinical research and discovery.  The company also offers the Voxel Tracker workstation software for visualizing and quantifying cells in MRI data sets. Customers include leading pharmaceutical and biotechnology companies and medical research centers worldwide. 

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com